JP2016502996A - ナイーブな対象のためのワクチン組成物 - Google Patents

ナイーブな対象のためのワクチン組成物 Download PDF

Info

Publication number
JP2016502996A
JP2016502996A JP2015547077A JP2015547077A JP2016502996A JP 2016502996 A JP2016502996 A JP 2016502996A JP 2015547077 A JP2015547077 A JP 2015547077A JP 2015547077 A JP2015547077 A JP 2015547077A JP 2016502996 A JP2016502996 A JP 2016502996A
Authority
JP
Japan
Prior art keywords
acid
composition
vaccine
influenza
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015547077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502996A5 (enExample
Inventor
ハンス アルヴィドソン
ハンス アルヴィドソン
アンナ−カリン マルタイス
アンナ−カリン マルタイス
Original Assignee
ユーロシネ ヴァクシンズ アクチエボラーグ
ユーロシネ ヴァクシンズ アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーロシネ ヴァクシンズ アクチエボラーグ, ユーロシネ ヴァクシンズ アクチエボラーグ filed Critical ユーロシネ ヴァクシンズ アクチエボラーグ
Publication of JP2016502996A publication Critical patent/JP2016502996A/ja
Publication of JP2016502996A5 publication Critical patent/JP2016502996A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
JP2015547077A 2012-12-17 2013-12-17 ナイーブな対象のためのワクチン組成物 Pending JP2016502996A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
EP12197522.1 2012-12-17
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019049330A Division JP2019112448A (ja) 2012-12-17 2019-03-18 ナイーブな対象のためのワクチン組成物

Publications (2)

Publication Number Publication Date
JP2016502996A true JP2016502996A (ja) 2016-02-01
JP2016502996A5 JP2016502996A5 (enExample) 2016-12-01

Family

ID=47358019

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015547077A Pending JP2016502996A (ja) 2012-12-17 2013-12-17 ナイーブな対象のためのワクチン組成物
JP2015547078A Pending JP2016502997A (ja) 2012-12-17 2013-12-17 免疫無防備状態の集団において使用するためのワクチン組成物
JP2019049330A Pending JP2019112448A (ja) 2012-12-17 2019-03-18 ナイーブな対象のためのワクチン組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015547078A Pending JP2016502997A (ja) 2012-12-17 2013-12-17 免疫無防備状態の集団において使用するためのワクチン組成物
JP2019049330A Pending JP2019112448A (ja) 2012-12-17 2019-03-18 ナイーブな対象のためのワクチン組成物

Country Status (12)

Country Link
US (2) US11065325B2 (enExample)
EP (4) EP2742952A1 (enExample)
JP (3) JP2016502996A (enExample)
KR (3) KR20150132093A (enExample)
CN (3) CN112826929A (enExample)
AU (2) AU2013360890B2 (enExample)
BR (2) BR112015014243A8 (enExample)
CA (2) CA2895023A1 (enExample)
HK (2) HK1213492A1 (enExample)
MX (2) MX2015007688A (enExample)
RU (2) RU2661408C2 (enExample)
WO (2) WO2014095944A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013007355A2 (pt) * 2010-09-30 2016-07-12 Eurocine Vaccines Ab composições de vacina aprimoradas
CA2962214A1 (en) 2014-09-26 2016-03-31 Seqirus UK Limited Vaccination of immunocompromised subjects
EP4144369A1 (en) * 2014-09-26 2023-03-08 Seqirus UK Limited Vaccination of immunocompromised subjects
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
LT4135520T (lt) * 2020-04-16 2024-12-27 Bayer Aktiengesellschaft Veikliųjų medžiagų deriniai ir juos apimančios fungicidų kompozicijos
BR112022020774A2 (pt) * 2020-04-16 2022-11-29 Bayer Ag Combinações de compostos ativos e composições fungicidas compreendendo as mesmas
LT4135521T (lt) * 2020-04-16 2025-01-10 Bayer Aktiengesellschaft Veikliųjų medžiagų deriniai ir juos apimančios fungicidų kompozicijos
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
WO2023133342A2 (en) * 2022-01-10 2023-07-13 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042003A1 (en) * 2010-09-30 2012-04-05 Eurocine Vaccines Ab Improved vaccine compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
ES2399386T3 (es) 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
AU2003301843A1 (en) 2002-05-17 2004-06-07 Human Genome Sciences, Inc. 157 human secreted proteins
DE60334145D1 (de) 2002-11-26 2010-10-21 Eurocine Vaccines Ab Neue adjuvant auf der basis von aminen
CN1867355A (zh) 2003-08-11 2006-11-22 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
CN103012169B (zh) 2005-06-30 2016-04-20 卫材R&D管理有限公司 用于制备免疫佐剂的化合物
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
EP2227251A1 (en) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition
AU2009293595A1 (en) 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
CA2826508C (en) 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
CA2764683A1 (en) 2009-05-28 2010-12-02 Joseph Collard Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042003A1 (en) * 2010-09-30 2012-04-05 Eurocine Vaccines Ab Improved vaccine compositions

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BARAS B, ET AL.: "Longevity of the protective immune response induced after vaccination with one or two doses of AS03A", VACCINE, vol. 29, no. 11, JPN6018013957, 13 January 2011 (2011-01-13), pages 2092 - 2099, ISSN: 0003921334 *
BARAS B, ET AL.: "Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naive ferrets", VACCINE, vol. 29, no. 11, JPN6018013954, 14 January 2011 (2011-01-14), pages 2120 - 2126, ISSN: 0003921335 *
LAMBKIN R, ET AL.: "Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-", VACCINE, vol. Vol.22, No.31-32, JPN6018013952, 2004, pages 4390 - 4396, ISSN: 0003921333 *
PETERSSON P, ET AL.: "The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after i", VACCINE, vol. 28, no. 39, JPN6017028568, 2010, pages 6491 - 6497, ISSN: 0003921329 *
出口 安裕: "インフルエンザワクチン 高齢者・ハイリスク者・医療介護従事者への接種", 臨牀と研究, vol. 第８１巻，１２号, JPN6017022992, December 2004 (2004-12-01), pages 1938 - 1942, ISSN: 0003921331 *
大藤 さとこ ほか: "インフルエンザワクチンの接種対象", 日本公衆衛生雑誌, vol. 第５４巻，第６号, JPN6017022995, 15 June 2007 (2007-06-15), pages 361 - 367, ISSN: 0003921330 *
相内 章 ほか: "経鼻投与型インフルエンザワクチンの実用化に向けて", インフルエンザ, vol. 第１３巻，第３号, JPN6017028570, October 2012 (2012-10-01), pages 199 - 204, ISSN: 0003780568 *
菅谷 憲夫: "インフルエンザワクチン", 小児科診療, vol. 第６７巻，第１１号, JPN6017022998, 2004, pages 1913 - 1918, ISSN: 0003921332 *
長谷川 秀樹: "経鼻粘膜投与型インフルエンザワクチンの開発", THE LUNG-PERSPECTIVES, vol. 第２０巻，第４号, JPN6017028572, November 2012 (2012-11-01), pages 418 - 422, ISSN: 0003780569 *

Also Published As

Publication number Publication date
AU2013360889A1 (en) 2015-07-02
JP2016502997A (ja) 2016-02-01
WO2014095944A1 (en) 2014-06-26
US11065325B2 (en) 2021-07-20
BR112015014243A2 (pt) 2017-07-11
AU2013360890B2 (en) 2017-04-13
EP2931308B1 (en) 2018-10-10
CA2895028A1 (en) 2014-06-26
BR112015014174A2 (pt) 2017-07-11
RU2661408C2 (ru) 2018-07-16
RU2015129028A (ru) 2017-01-23
BR112015014243A8 (pt) 2019-10-08
JP2019112448A (ja) 2019-07-11
HK1212611A1 (zh) 2016-06-17
KR20150132093A (ko) 2015-11-25
WO2014095943A1 (en) 2014-06-26
US20150306204A1 (en) 2015-10-29
AU2013360889B2 (en) 2016-12-01
RU2661407C2 (ru) 2018-07-16
MX2015007753A (es) 2016-01-08
EP2931307B1 (en) 2018-09-12
EP2931307A1 (en) 2015-10-21
AU2013360889C1 (en) 2017-06-08
EP2742952A1 (en) 2014-06-18
CN112826929A (zh) 2021-05-25
KR20210007042A (ko) 2021-01-19
AU2013360890A1 (en) 2015-07-02
EP2931308A1 (en) 2015-10-21
CA2895023A1 (en) 2014-06-26
RU2015129077A (ru) 2017-01-23
CN104870010A (zh) 2015-08-26
CN104884085A (zh) 2015-09-02
KR20150132092A (ko) 2015-11-25
US20150306205A1 (en) 2015-10-29
EP3431101A1 (en) 2019-01-23
HK1213492A1 (zh) 2016-07-08
MX2015007688A (es) 2015-09-07

Similar Documents

Publication Publication Date Title
JP2019112448A (ja) ナイーブな対象のためのワクチン組成物
Nitika et al. The development of mRNA vaccines for infectious diseases: recent updates
CN102395600B (zh) 含有无铝佐剂的灭活的登革热病毒疫苗
TWI737584B (zh) 手、足及口疫苗及其製備及使用方法
KR20140033171A (ko) 비활성화된 뎅기 바이러스 백신
BE1022008B1 (fr) Compositions immunogenes combinees
AU2014251247A1 (en) Vaccine composition and method of use
JP2019520090A (ja) 弱毒変異型ジカウイルスを含むワクチン組成物
JP2011525902A (ja) 遅延型追加刺激免疫処置に対する迅速な応答
JP2009209086A (ja) 粘膜投与型ワクチン
JP2011057605A (ja) 粘膜投与型ワクチン
JP2018172434A (ja) 鼻腔内予防接種投薬レジメン
JP2023091085A (ja) 粘膜アジュバント
Morelli et al. ISCOMATRIX adjuvant in the development of prophylactic and therapeutic vaccines
US20080038294A1 (en) Intranasal or inhalational administration of virosomes
Willis The Effect of Maternal Antibodies on Anti-viral Immunity in Infant Mice
Herzog Epaxal®: clinical experience with the only aluminium-free hepatitis A vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181119